Santa Rosa medical technology startup Osseon Therapeutics is growing, with new funding and product launches outside the U.S.
The four-year-old firm makes a next-generation system for repairing spinal fractures.
"We expect to triple our sales by the end of the year," Osseon CEO John Stalcup said Thursday.
Osseon's technology targets a $1.6 billion to $3 billion global market for treatments of vertebral compression fractures. They are mostly caused by osteoporosis, which affects about 10 million people in the U.S.
The demand is growing as the population ages, Stalcup said. Most compression fractures happen to women over 50.
The Obama Administration's health care program also promises to drive sales by bringing millions of new patients into the health system, Stalcup said.
Osseon's repair system includes a steerable, curvable needle for injecting bone cement into fractured vertebrae.
The treatment stabilizes the fracture and relieves pain.
Osseon's system is an improvement because it uses a needle that delivers orthopedic cement to a damaged vertebra with a single insertion, Stalcup said. Conventional systems involve two insertions on opposite sides of the vertebra.
Osseon's treatment is faster, safer and less painful than other technologies, he said.